Zeltiq Aesthetics Inc (ZLTQ) : Lamond Capital Partners has sold out all of its stake in Zeltiq Aesthetics Inc during the most recent quarter, according to the disclosure filed by the company on Jul 19, 2016 with the SEC. The investment management company has sold out 16,119 shares of Zeltiq Aesthetics Inc which is valued at $521,933.
Other Hedge Funds, Including , St. Johns Investment Management Company added ZLTQ to its portfolio by purchasing 170 company shares during the most recent quarter which is valued at $5,505.Simplex Trading reduced its stake in ZLTQ by selling 5,122 shares or 78.06% in the most recent quarter. The Hedge Fund company now holds 1,440 shares of ZLTQ which is valued at $46,627. Zeltiq Aesthetics Inc makes up approx 0.01% of Simplex Trading’s portfolio.Eqis Capital Management boosted its stake in ZLTQ in the latest quarter, The investment management firm added 1,607 additional shares and now holds a total of 23,806 shares of Zeltiq Aesthetics Inc which is valued at $752,032. Zeltiq Aesthetics Inc makes up approx 0.05% of Eqis Capital Management’s portfolio.Creative Planning reduced its stake in ZLTQ by selling 450 shares or 69.55% in the most recent quarter. The Hedge Fund company now holds 197 shares of ZLTQ which is valued at $6,198. Hamilton Lane Advisors sold out all of its stake in ZLTQ during the most recent quarter. The investment firm sold 66,749 shares of ZLTQ which is valued $2,099,924.
Zeltiq Aesthetics Inc opened for trading at $31.49 and hit $32.54 on the upside on Wednesday, eventually ending the session at $32.38, with a gain of 3.06% or 0.96 points. The heightened volatility saw the trading volume jump to 5,12,334 shares. Company has a market cap of $1,278 M.
On the company’s financial health, Zeltiq Aesthetics Inc reported $-0.25 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on May 10, 2016. Analyst had a consensus of $-0.24. The company had revenue of $64.50 million for the quarter, compared to analysts expectations of $61.87 million. The company’s revenue was up 25.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.06 EPS.
ZELTIQ Aesthetics Inc. is a medical technology company. The Company is focused on developing and commercializing products utilizing its controlled-cooling technology platform. Its commercial product the CoolSculpting System is designed to reduce stubborn fat bulges. The Company sells its CoolSculpting system to dermatologists plastic surgeons and aesthetic specialists and generates revenue from sales of its CoolSculpting system and from sales of consumables to its customers. Consumables are the CoolSculpting procedure packs that it sells which are needed to perform procedures using its CoolSculpting system. As of December 31 2014 it had an installed base of 3176 CoolSculpting systems installed across approximately 2688 practices across the world. As of December 31 2014 1.5 million CoolSculpting cycles had been shipped to its customers and distributors.